Advertisement

Fertility Preservation in the Female Cancer Patient

  • Rebecca FlycktEmail author
  • Tommaso Falcone
Chapter
Part of the Current Clinical Urology book series (CCU)

Abstract

Advances in chemotherapy options have led to significantly increased survival rates in reproductive-aged women with cancer. Among the many concerns of young female cancer patients is whether they will be able to conceive and deliver a healthy baby once their cancer treatments are complete. Fortunately, there are a number of fertility preservation options available for women facing chemotherapy, surgery, bone marrow transplantation, and pelvic radiation. All of these cancer treatments have been associated with irreversible loss of oocytes and ovarian function. Fertility preservation options range from medical and surgical treatments to oocyte or embryo cryopreservation using established in vitro fertilization techniques. Experimental modalities such as ovarian tissue freezing and in vitro maturation of immature oocytes are also discussed in this chapter. Standard techniques for in vitro fertilization will be discussed in more detail in a subsequent chapter.

Keywords

Oocyte cryopreservation Embryo cryopreservation Ovarian tissue cryopreservation Emergency IVF GnRH agonists Ovarian transposition 

References

  1. 1.
    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65(1):5–29.CrossRefPubMedGoogle Scholar
  2. 2.
    Banerjee R, Tsiapali E. Occurrence and recall rates of fertility discussions with young breast cancer patients.Support Care Cancer. 2016 Jan;24(1):163–71.Google Scholar
  3. 3.
    Armuand GM, Rodriguez-Wallberg KA, Wettergren L, Ahlgren J, Enblad G, Hoglund M, Lampic C. Sex differences in fertility-related information received by young adult cancer survivors. J Clin Oncol. 2012;30(17):2147–53.CrossRefPubMedGoogle Scholar
  4. 4.
  5. 5.
    Meirow D, Nugent D. The effects of radiotherapy and chemotherapy on female reproduction. Hum Reprod Update. 2001;7(6):535–43.CrossRefPubMedGoogle Scholar
  6. 6.
    Moore HC. Fertility and the impact of systemic therapy on hormonal status following treatment for breast cancer. Curr Oncol Rep. 2000;2(6):587–93.CrossRefPubMedGoogle Scholar
  7. 7.
    Anderson RA, Wallace WH. Antimüllerian hormone, the assessment of the ovarian reserve, and the reproductive outcome of the young patient with cancer. Fertil Steril. 2013;99(6):1469–75. doi: 10.1016/j.fertnstert.2013.03.014. Epub 2013 Mar 27.CrossRefPubMedGoogle Scholar
  8. 8.
    Wallace WH, Shalet SM, Hendry JH, Morris-Jones PH, Gattamaneni HR. Ovarian failure following abdominal irradiation in childhood: the radiosensitivity of the human oocyte. Br J Radiol. 1989;62(743):995–8.CrossRefPubMedGoogle Scholar
  9. 9.
    Wallace WH, Thomson AB, Kelsey TW. The radiosensitivity of the human oocyte. Hum Reprod. 2003;18(1):117–21.CrossRefPubMedGoogle Scholar
  10. 10.
    Wo JY, Viswanathan AN. Impact of radiotherapy on fertility, pregnancy, and neonatal outcomes in female cancer patients. Int J Radiat Oncol Biol Phys. 2009;73(5):1304–12.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Larsen EC, Schmiegelow K, Rechnitzer C, Loft A, Muller J, Andersen AN. Radiotherapy at a young age reduces uterine volume of childhood cancer survivors. Acta Obstet Gynecol Scand. 2004;83:96–102.CrossRefPubMedGoogle Scholar
  12. 12.
    Ghadjar P, Budach V, Köhler C, Jantke A, Marnitz S. Modern radiation therapy and potential fertility preservation strategies in patients with cervical cancer undergoing chemoradiation. Radiat Oncol. 2015;10:5.CrossRefGoogle Scholar
  13. 13.
    Bedaiwy MA, Abou-Setta AM, Desai N, Hurd W, Starks D, El-Nashar SA, Al-Inany HG, Falcone T. Gonadotropin-releasing hormone analog cotreatment for preservation of ovarian function during gonadotoxic chemotherapy: a systematic review and meta-analysis. Fertil Steril. 2011;95(3):906–14.e1–4.CrossRefPubMedGoogle Scholar
  14. 14.
    Wang C, Chen M, Fu F, Huang M. Gonadotropin-releasing hormone analog cotreatment for the preservation of ovarian function during gonadotoxic chemotherapy for breast cancer: a meta-analysis. PLoS One. 2013;8(6), e66360.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Vitek WS, Shayne M, Hoeger K, Han Y, Messing S, Fung C. Gonadotropin-releasing hormone agonists for the preservation of ovarian function among women with breast cancer who did not use tamoxifen after chemotherapy: a systematic review and meta-analysis. Fertil Steril. 2014;102(3):808–15.e1.CrossRefPubMedGoogle Scholar
  16. 16.
    Munster PN, Moore AP, Ismail-Khan R, Cox CE, Lacevic M, Gross-King M, Xu P, Carter WB, Minton SE. Randomized trial using gonadotropin-releasing hormone agonist triptorelin for the preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer. J Clin Oncol. 2012;30(5):533–8.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Elgindy EA, El-Haieg DO, Khorshid OM, Ismail EI, Abdelgawad M, Sallam HN, Abou-Setta AM. Gonadatrophin suppression to prevent chemotherapy-induced ovarian damage: a randomized controlled trial. Obstet Gynecol. 2013;121(1):78–86.CrossRefPubMedGoogle Scholar
  18. 18.
    Demeestere I, Brice P, Peccatori FA, Kentos A, Gaillard I, Zachee P, Casasnovas RO, Van Den Neste E, Dechene J, De Maertelaer V, Bron D, Englert Y. Gonadotropin-releasing hormone agonist for the prevention of chemotherapy-induced ovarian failure in patients with lymphoma: 1-year follow-up of a prospective randomized trial. J Clin Oncol. 2013;31(7):903–9.CrossRefPubMedGoogle Scholar
  19. 19.
    Chen H, Li J, Cui T, Hu L. Adjuvant gonadotropin-releasing hormone analogues for the prevention of chemotherapy induced premature ovarian failure in premenopausal women. Cochrane Database Syst Rev. 2011;(11):CD008018.Google Scholar
  20. 20.
    Blumenfeld Z. How to preserve fertility in young women exposed to chemotherapy? The role of GnRH agonist cotreatment in addition to cryopreservation of embrya, oocytes, or ovaries. Oncologist. 2007;12(9):1044–54.CrossRefPubMedGoogle Scholar
  21. 21.
    Moore HC, Unger JM, Phillips KA, Boyle F, Hitre E, Porter D, Francis PA, Goldstein LJ, Gomez HL, Vallejos CS, Partridge AH, Dakhil SR, Garcia AA, Gralow J, Lombard JM, Forbes JF, Martino S, Barlow WE, Fabian CJ, Minasian L, Meyskens Jr FL, Gelber RD, Hortobagyi GN, Albain KS, POEMS/S0230 Investigators. Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. N Engl J Med. 2015;372(10):923–32.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Morice P, Juncker L, Rey A, El-Hassan J, Haie-Meder C, Castaigne D. Ovarian transposition for patients with cervical carcinoma treated by radiosurgical combination. Fertil Steril. 2000;74(4):743–8.CrossRefPubMedGoogle Scholar
  23. 23.
    Ross L, Chung K, Macdonald H. Fertility preservation in the female cancer patient. J Surg Oncol. 2014;110(8):907–11.CrossRefPubMedGoogle Scholar
  24. 24.
    Gunderson CC, Fader AN, Carson KA, Bristow RE. Oncologic and reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 adenocarcinoma: a systematic review. Gynecol Oncol. 2012;125(2):477–82.CrossRefPubMedGoogle Scholar
  25. 25.
    Ethics Committee of American Society for Reproductive Medicine. Fertility preservation and reproduction in patients facing gonadotoxic therapies: a committee opinion. Fertil Steril. 2013;100(5):1224–31.CrossRefGoogle Scholar
  26. 26.
    Baynosa J, Westphal LM, Madrigrano A, Wapnir I. Timing of breast cancer treatments with oocyte retrieval and embryo cryopreservation. J Am Coll Surg. 2009;209(5):603–7.CrossRefPubMedGoogle Scholar
  27. 27.
    Cakmak H, Katz A, Cedars MI, Rosen MP. Effective method for emergency fertility preservation: random-start controlled ovarian stimulation. Fertil Steril. 2013;100(6):1673–80.CrossRefPubMedGoogle Scholar
  28. 28.
    Corbett S, Shmorgun D, Claman P; Reproductive Endocrinology Infertility Committee, Healey S, Gysler M. The prevention of ovarian hyperstimulation syndrome. J Obstet Gynaecol Can. 2014;36(11):1024–36.Google Scholar
  29. 29.
    Johnson LN, Dillon KE, Sammel MD, Efymow BL, Mainigi MA, Dokras A, Gracia CR. Response to ovarian stimulation in patients facing gonadotoxic therapy. Reprod Biomed Online. 2013;26(4):337–44.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Domingo J, Guillén V, Ayllón Y, Martínez M, Muñoz E, Pellicer A, Garcia-Velasco JA. Ovarian response to controlled ovarian hyperstimulation in cancer patients is diminished even before oncological treatment. Fertil Steril. 2012;97(4):930–4.CrossRefPubMedGoogle Scholar
  31. 31.
    Friedler S, Koc O, Gidoni Y, Raziel A, Ron-El R. Ovarian response to stimulation for fertility preservation in women with malignant disease: a systematic review and meta-analysis. Fertil Steril. 2012;97(1):125–33.CrossRefPubMedGoogle Scholar
  32. 32.
    Chung K, Donnez J, Ginsburg E, Meirow D. Emergency IVF versus ovarian tissue cryopreservation: decision making in fertility preservation for female cancer patients. Fertil Steril. 2013;99(6):1534–42.CrossRefPubMedGoogle Scholar
  33. 33.
    Practice Committees of American Society for Reproductive Medicine; Society for Assisted Reproductive Technology. Mature oocyte cryopreservation: a guideline. Fertil Steril. 2013;99(1):37–43.CrossRefGoogle Scholar
  34. 34.
    Nagy ZP, Chang CC, Shapiro DB, Bernal DP, Kort HI, Vajta G. The efficacy and safety of human oocyte vitrification. Semin Reprod Med. 2009;27(6):450–5.CrossRefPubMedGoogle Scholar
  35. 35.
    Cobo A, Diaz C. Clinical application of oocyte vitrification: a systematic review and meta-analysis of randomized controlled trials. Fertil Steril. 2011;96(2):277–85.CrossRefPubMedGoogle Scholar
  36. 36.
    Cil AP, Bang H, Oktay K. Age-specific probability of live birth with oocyte cryopreservation: an individual patient data meta-analysis. Fertil Steril. 2013;100(2):492–9.e3.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Donnez J, Dolmans MM. Fertility preservation in women. Nat Rev Endocrinol. 2013;9(12):735–49.CrossRefPubMedGoogle Scholar
  38. 38.
    Noyes N, Porcu E, Borini A. Over 900 oocyte cryopreservation babies born with no apparent increase in congenital anomalies. Reprod Biomed Online. 2009;18(6):769–76.CrossRefPubMedGoogle Scholar
  39. 39.
    Garcia-Velasco JA, Domingo J, Cobo A, Martínez M, Carmona L, Pellicer A. Five years’ experience using oocyte vitrification to preserve fertility for medical and nonmedical indications.Fertil Steril. 2013;99(7):1994–9.CrossRefPubMedGoogle Scholar
  40. 40.
    Donnez J, Dolmans MM. Preservation of fertility in females with haematological malignancy. Br J Haematol. 2011;154(2):175–84.CrossRefPubMedGoogle Scholar
  41. 41.
    Donnez J, Dolmans MM, Pellicer A, Diaz-Garcia C, Sanchez Serrano M, Schmidt KT, Ernst E, Luyckx V, Andersen CY. Restoration of ovarian activity and pregnancy after transplantation of cryopreserved ovarian tissue: a review of 60 cases of reimplantation. Fertil Steril. 2013;99(6):1503–13.CrossRefPubMedGoogle Scholar
  42. 42.
    Stern CJ, Gook D, Hale LG, Agresta F, Oldham J, Rozen G, Jobling T. First reported clinical pregnancy following heterotopic grafting of cryopreserved ovarian tissue in a woman after a bilateral oophorectomy. Hum Reprod. 2013;28(11):2996–9.CrossRefPubMedGoogle Scholar
  43. 43.
    Meirow D, Fasouliotis SJ, Nugent D, Schenker JG, Gosden RG, Rutherford AJ. A laparoscopic technique for obtaining ovarian cortical biopsy specimens for fertility conservation in patients with cancer. Fertil Steril. 1999;71(5):948–51.CrossRefPubMedGoogle Scholar
  44. 44.
    Jadoul P, Dolmans MM, Donnez J. Fertility preservation in girls during childhood: is it feasible, efficient and safe and to whom should it be proposed? Hum Reprod Update. 2010;16(6):617–30.CrossRefPubMedGoogle Scholar
  45. 45.
    Dolmans MM, Marinescu C, Saussoy P, Van Langendonckt A, Amorim C, Donnez J. Reimplantation of cryopreserved ovarian tissue from patients with acute lymphoblastic leukemia is potentially unsafe. Blood. 2010;116(16):2908–14.CrossRefPubMedGoogle Scholar
  46. 46.
    Dolmans MM, Luyckx V, Donnez J, Andersen CY, Greve T. Risk of transferring malignant cells with transplanted frozen-thawed ovarian tissue. Fertil Steril. 2013;99(6):1514–22.CrossRefPubMedGoogle Scholar
  47. 47.
    Gremeau AS, Andreadis N, Fatum M, Craig J, Turner K, McVeigh E, Child T. In vitro maturation or in vitro fertilization for women with polycystic ovaries? A case-control study of 194 treatment cycles. Fertil Steril. 2012;98(2):355–60.CrossRefPubMedGoogle Scholar
  48. 48.
    De Vos M, Smitz J, Woodruff TK. Fertility preservation in women with cancer. Lancet. 2014;384(9950):1302–10.CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Prasath EB, Chan ML, Wong WH, Lim CJ, Tharmalingam MD, Hendricks M, Loh SF, Chia YN. First pregnancy and live birth resulting from cryopreserved embryos obtained from in vitro matured oocytes after oophorectomy in an ovarian cancer patient. Hum Reprod. 2014;29(2):276–8.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  1. 1.Reproductive Endocrinology and InfertilityCleveland Clinic, Beachwood Family Health CenterBeachwoodUSA
  2. 2.Obstetrics Gynecology and Womens Health InstituteCleveland ClinicClevelandUSA

Personalised recommendations